The diagnostics company recorded 15.6% increase year-on-year in revenue from operations to Rs 223 crore in Q2 September 2019, driven by volume growth and organic expansion. The result was announced on Tuesday, 12 November 2019.

Accounting EBIDTA recorded 18.8% growth at Rs 63 crore in Q2 September 2019 over Q2 September 2018, representing 28% of the company's revenue.

Total number of patients visited increased by 15.7% to 2.66 million patients in Q2 September 2019 as compared to the corresponding quarter in the last fiscal. The total number of tests conducted stood at 5.17 million in Q2 FY20, up by 20.1% from Q2 FY19.

Acquisition of 4 front end labs in Surat helped the company expand its market share in the focus city. A total of 14 new tests have been validated and added to the test menu in H1FY20 thus expanding our capabilities to do more specialized tests.

Ameera Shah, managing director, Metropolis Healthcare, said, "We have been witnessing a rapid growth in number of tests and patient visits, outpacing the industry. This is evident from the increase in revenue contribution from our retail business which reinforces patient trust and preference for Metropolis. In our endeavor to offer tests that are critical for correct diagnosis, we have added 14 new specialized tests in the area of oncology, genetics and transplant pathology."

The scrip was up 0.52% at Rs 1408.10. It traded in the range of Rs 1400.75 and Rs 1440 so far during the day.

Metropolis Healthcare is a leading diagnostics company in India with a widespread presence across 19 states in India. Metropolis offers a comprehensive range of 4000 plus tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases and an array of genetic abnormalities.